ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
|Name||Chg %||Market Cap|
|Eli Lilly & Co.||$234.15B|
|Vanda Pharmaceuticals Inc.||$1.09B|
|Johnson & Johnson||$452.39B|
|Bristol Myers Squibb Co.||$152.67B|
|Adamas Pharmaceuticals Inc.||$224.32M|
|Catalyst Biosciences Inc.||$135.12M|